Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital

Pathology

Volumn 38, Issue 1, 2006, Pages 49-52

  Gillett, Melissa J ^a   Vasikaran, Samuel D ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Audit; Cross linked N terminal telopeptide of type I collagen; NTX; Osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; TESTOSTERONE;

ARTICLE; BONE DENSITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PHYSICIAN; TERTIARY HEALTH CARE; TIME SERIES ANALYSIS; UNSPECIFIED SIDE EFFECT; URINE LEVEL;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CASE MANAGEMENT; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOSPITALS; HUMANS; MEDICAL AUDIT; OSTEOPOROSIS; PATIENT COMPLIANCE; PEPTIDES; RETROSPECTIVE STUDIES;

EID: 32944462178     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500459623     Document Type: Article

References (14)

1. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; (Suppl 6): S2-17.
2. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337-49.
3. Worsfold M, Powell DE, Jones TJW, Davie MWJ. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem 2004; 50: 2263-70.
4. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with residronate. J Bone Miner Res 2003; 18: 1051-6.
5. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285: 785-95.
6. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102: 29-37.
7. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.
9. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81: 961-7.
10. Takami H, Ikeda Y, Hayashi K, et al. Clinical assessment of collagen cross-linked N-telopeptides as a marker of bone metabolism in patients with primary hyperparathyroidism. Biomed Pharmacother 1999; 53: 329-33.
11. Glendenning P, Kent GN, Adler BD, et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol (Oxf) 1999; 50: 347-55.
12. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastro-intestinal complaints non-compliance with patient instructions and discontinuation. J Managed Care Pharm 1998; 4: 488-92.
13. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001; 8: 328-32.
14. Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000; 15: 594-8.